Toremifene use does not alter serum inhibin A and B levels during mid-luteal phase in women with premenstrual mastalgia

Gynecological Endocrinology

Volumn 26, Issue 2, 2010, Pages 114-117

  Oksa, Sinikka ^a   Luukkaala, Tiina ^b,c   Mäenpää, Johanna U ^c,d,e  

^a SATAKUNTA CENTRAL HOSPITAL   (Finland)

^b PIRKANMAA HOSPITAL DISTRICT   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Breast; Inhibin A; Inhibin B; Mastalgia; Premenstrual syndrome; SERM; Toremifene

Indexed keywords

INHIBIN A; INHIBIN B; PLACEBO; TOREMIFENE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SYNTHESIS; HUMAN; LUTEAL PHASE; MASTALGIA; MENSTRUAL CYCLE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROSS-OVER STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INHIBINS; LUTEAL PHASE; MIDDLE AGED; PREMENSTRUAL SYNDROME; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TOREMIFENE;

EID: 75449110739     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903215441     Document Type: Article

References (25)

1. Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am J Obstet Gynecol 1997;177:126-132.
2. Millet AV, Dirbas FM. Clinical management of breast pain: a review. Obstet Gynecol Surv 2002;57:451-461.
3. BeLieu RM. Mastodynia. Obstet Gynecol Clin North Am 1994;21:461-467.
4. Mansel RE, Dogliotti L. European multicentre trial of bromocriptine in cyclical mastalgia. Lancet 1990;335:190-193.
5. Smith RL, Pruthi S, Fitzpatrick LA. Evaluation and management of breast pain. Mayo Clin Proc 2004;79:353-372.
6. England PC, Skinner LG, Cotrell KM, Sellwood LA. Sex hormones in breast disease. Br J Surg 1975;62:806-809.
7. Ayers JW, Gidwani GP. The "luteal breast": hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia. Fertil Steril 1983;40:779-784.
8. Graziottin A, Sopracordevole F, Velasco M, Grella PV. Plasma prolactin in women with mastodynia. Clin Exp Obstet Gynecol 1984;11:113-116.
9. Eriksson E, Sunblad C, Lisjö P, Modigh K, Andersch B. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992;17:195-204.
10. Robertson DM, Foulds LM, Leversha L, Morgan FJ, Hearn MTW, Burger HG, Wettenhall, REH, de Kretser DM. Isolation of inhibin from bovine follicular fluid. Biochem Biophys Res Commun 1985;126:220-226.
11. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401-1405.
12. Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol 1997;11:393-397.
13. Oksa S, Luukkaala T, Mäenpää J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG 2006;113:1-6.
14. Tajima C. Luteotropic effects of tamoxifen in infertile women. Fertil Steril 1984;42:223-227.
15. Oksa S, Luukkaala T, Mäenpää J. The antioestrogen toremifene has luteotropic effects in women suffering from premenstrual mastalgia. Acta Endocrinol 2008;4:425-432.
16. Yamoto M, Minami S, Nakano R, Kobayashi M. Immunohistochemical localization of inhibin/activin subunits in human ovarian follicles during the menstrual cycle. J Clin Endocrinol 1992;74:989-993.
17. Erämaa M, Heikinheimo K, Tuuri T, Hilden K, Ritvos O. Inhibin/activin subunit expression in human granulosa-luteal cells. Mol Cell Endocrinol 1993;92:R15-R20.
18. Navarrete MA, Maier CM, Falzoni R, Quadros LG, Lima GR, Baracat EC, Nazario AC. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005;7: R306-R313.
19. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not endogenous human prolactin induces estrogen receptor a and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 2004;88:69-77.
20. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003;86:245-253.
21. Chatterton RT Jr, Geiger AS, Khan SA, Helenowski IB, Jovanovic BD, Gann PH. Variation in estradiol, estradiol precursors, and estrogen-related products in nipple aspirate fluid from normal premenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:928-935.
22. Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH. Hormone levels in nipple aspirate fluid (NAF) of pre- and post-menopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 2005;90:1686-1691.
23. Dabrosin C. Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle. J Endocrinol 2005;187:103-108.
24. Uehara J, Nazário AC, Rodrigues de Lima G, Simões MJ, Juliano Y, Gebrim LH. Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle. Int J Gynaecol Obstet 1998;62:77-82.
25. Facina G, de Lima GR, Simões MJ, Novo NF, Gebrim LH. Estrogenic activity of tamoxifen on normal mammary parenchyma in the luteal phase of the menstrual cycle. Int J Gynaecol Obstet 1997;56:19-24.